Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP2 | Q9HC62 | 3/20 | 0.69 |
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.69 |
| ▸ | SUMO2 | P61956 | 2/20 | 0.69 |
| ▸ | SUMO1 | P63165 | 2/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.69 |
| ▸ | SENP3 | Q9H4L4 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | SNCA | P37840 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044324 | 0.92 | SENP2 (0.63) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL15120173 | 0.92 | SENP2 (0.63) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL29697088 | 0.92 | SENP2 (0.63) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL14988806 | 0.91 | SENP2 (0.62) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL14988808 | 0.91 | SENP2 (0.62) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL18044194 | 0.91 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL15120146 | 0.91 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL29697126 | 0.91 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL18044286 | 0.91 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL29697216 | 0.91 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216397-A1 | COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY | KYOTO UNIVERSITY (JP) | 2024-07-04 | — | — | US | disclosed |
| US-9931351-B2 | Method for improving leptin resistance | KYOTO UNIVERSITY (JP) | 2018-04-03 | — | — | US | disclosed |
| US-9782420-B2 | Method for treating eye diseases | KYOTO UNIVERSITY (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20160303144-A1 | Medicinal Composition Improving Leptin Resistance | KYOTO UNIVERSITY (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160000810-A1 | Method For Treating Eye Diseases | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | disclosed |
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000810-A1 | Method For Treating Eye Diseases | CFB, AGER, CFH | SENP2 3567/4885SENP1 3495/4885SUMO2 3428/4885 |
| US-20160303144-A1 | Medicinal Composition Improving Leptin Resistance | LIPC, ADIPOR1, GPR119 | SENP2 3218/4885SENP1 3152/4885SUMO2 4540/4885 |
| US-20240216397-A1 | COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY | CUTA, FABP4, MMP13 | SENP2 3876/4885SENP1 3680/4885SUMO2 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.